<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

NEWSROOM Press Releases

    Year
    2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

    254 Results

    Biodesix Announces VeriStrat® Data in Head and Neck Cancer to be Presented at ASCO

    May 14, 2009

    Christine Chung, MD, Assistant Professor of Medicine at Vanderbilt University will be presenting data on Veristrat at the 45th Annual Meeting of ASCO.

    Biodesix Announces New VeriStrat® Data to be Presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology

    August 23, 2012

    Results from two phase II advanced lung cancer trials will be presented at the upcoming 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

    Lung Cancer Study Evaluating Changes in VeriStrat Status over the Course of Treatment with Gefitinib Published in Journal of Thoracic Oncology

    November 2, 2011

    Publication announced today: Changes in plasma mass-spectral (VeriStrat) profile in course of treatment of NSCLC patients with EGFR-TKIs.

    Biodesix Advances the Field of Personalized Medicine with the Launch of VeriStrat®

    May 5, 2009

    Biodesix announces the U.S. commercial availability of VeriStrat.

    VeriStrat® Results Correlate with Survival Outcomes in Kidney Cancer Patients

    October 18, 2011

    Data show that VeriStrat was able to stratify renal cell carcinoma (RCC) patients treated with a combination of two targeted therapies.

    VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer

    April 23, 2012

    VeriStrat test was able to identify patients likely to have better and worse survival outcomes when treated with the combination therapy.

    VeriStrat® Test Identifies Lung Cancer Patients Benefiting from Combination Therapy

    November 19, 2010

    The intention of the biomarker analysis was to evaluate the ability of VeriStrat, to predict patient outcomes with a combination regimen.

    Biodesix Supports Unique Lung Cancer Research Initiative – CASTLE study enrolls initial subjects

    May 6, 2011

    Biodesix announces the enrollment of initial subjects into CASTLE, the inaugural study of the Addario Lung Cancer Medical Institute.

    Biodesix Announces Phase 3 Clinical Trial Collaboration with Kadmon

    February 27, 2012

    Biodesix today announced a collaboration with Kadmon Corporation, LLC, to explore the utility of Biodesix’ VeriStrat® test in a Phase 3 (NSCLC).
    1 2